The Center for Cancer and Blood Disorders (The CenterTX) in the US is set to deploy Deep Lens’ artificial intelligence (AI)-based clinical trial screening and enrolment solution VIPER.

Using Cloud-based technology, VIPER will facilitate, triage, and accelerate the clinical trial recruitment process.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Through its partnership with Deep Lens, The CenterTX will broaden its clinical trial offering by improving efficiencies related to recruitment and expanding the number of available trials for eligible subjects.

The CenterTX serves patients across ten locations in North Texas.

The CenterTX CEO Barry Russo said: “We are a forward-looking practice that takes pride in our ability to offer our patient community a robust suite of services and cutting-edge treatment options designed to meet their individual needs.

“We are very excited to integrate VIPER into our clinical trial programme, as it will not only help assist in growing our research capabilities, but it will also provide the practice with quality metrics, improved operational support and present our care teams a more effective method by which to match patients to trials.”

By integrating directly into The CenterTX’s EMR (VieCure), molecular data feeds and pathology feeds, VIPER will automatically identify qualified patients for clinical trials.

Deep Lens chief revenue officer Greg Andreola said: “This collaboration will provide The CenterTX the ability to accelerate enrolment in clinical trials and will help reinforce its leadership in the oncology community by offering an increased number of precision medicine trials.”

Last month, cancer care network Oncology and Hematology Specialists collaborated with Deep Lens to integrate VIPER.